Anixa Biosciences, Inc. (FRA:CY71)
2.700
+0.040 (1.50%)
At close: Jan 2, 2026
Anixa Biosciences Employees
Anixa Biosciences had 5 employees as of October 31, 2024. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
€1,943,347
Market Cap
95.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Oct 31, 2024 | 5 | 0 | - |
| Oct 31, 2023 | 5 | 0 | - |
| Oct 31, 2022 | 5 | 0 | - |
| Oct 31, 2021 | 5 | 1 | 25.00% |
| Oct 31, 2020 | 4 | -4 | -50.00% |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Anixa Biosciences News
- 27 days ago - Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Development - GuruFocus
- 27 days ago - Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - PRNewsWire
- 4 weeks ago - Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine Data - GuruFocus
- 4 weeks ago - Anixa Biosciences falls on phase 1 data for breast cancer vaccine - Seeking Alpha
- 4 weeks ago - Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why - Benzinga
- 4 weeks ago - Anixa Biosciences' Breast Cancer Vaccine Safe, Well Tolerated In Phase 1 Study - Nasdaq
- 4 weeks ago - Anixa Biosciences (ANIX) Presents Promising Phase 1 Breast Cancer Vaccine Results - GuruFocus
- 4 weeks ago - Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants - PRNewsWire